Matthew R. Pincus, MD, PhD, professor of pathology at SUNY Downstate and chairman of pathology and laboratory medicine at the Brooklyn VA, said, "The results are very encouraging. PNC-28 may be an effective agent in treating cancers, especially if delivered directly to the tumor."
PNC-28 is a p53 peptide, a naturally occurring human protein known to suppress tumor growth. The researchers previously found that PNC-28 induces death of a variety of human tumor cell lines, including a pancreatic cancer cell line, while not harming healthy cells.
The research team has now given PNC-28 to laboratory animals to test its ability to block the growth of pancreatic cancer cells. When administered over a two-week period in the peritoneal cavities of mice containing simultaneously transplanted tumors, PNC-28 caused complete destruction of these tumors.
When delivered concurrently with tumor implantation, PNC-28 completely blocked tumor growth during the two-week period of administration and two weeks post-treatment, followed by weak tumor growth that leveled off at low tumor sizes.
In addition, according to Josef Michl, MD, associate professor of pathology at SUNY Downstate, "When administered from a site distant from the tumor, PNC-28 still caused a decrease in tumor size. This tumor growth was significantly slower than growth in the presence of a control peptide."
Dr. Pincus added that this peptide and its parent peptide, called PNC-27, are lethal to a wide variety of human cancer cells, besides pancreatic cancer, including colon, breast, cervical and bone (osteogenic sarcoma) cancers. These peptides kill cancer cells that do not even
Source:SUNY Downstate Medical Center